Skip to content
The Future Explorerby Benjamin Talin
Enablertechnological

BioTech & Genomics

Reading, understanding and editing the instructions inside living things, their DNA. Reading a whole human genome cost about $95 million in 2001 and about $525 two decades later, a faster fall than computer chips ever managed. That cheap reading powers new tests and medicines. Fixing what we read is far slower: the first gene-editing cure for sickle cell disease had reached only a few dozen patients worldwide almost two years after approval.

Maturity

3/ 5
measured
BasisReading a genome is cheap and routine - about $525 at NHGRI's last measurement. Acting on it is not: almost two years after approval, the first CRISPR medicine had been infused into 39 patients worldwide. The score is the slower of the two.SourceNHGRI Genome Sequencing Program cost data (Wetterstrand; last point May 2022, page updated 16 May 2023); FDA (8 Dec 2023); CRISPR Therapeutics Q3 2025 results (10 Nov 2025, company-reported); Orchard Therapeutics (20 Mar 2024)Vintage2001–2025
ReadinessCapability 5Deployment 3Absorption 3Bound bycapitalTrendflat

Where it feeds in

4 megatrends in 4 forces

Where you have already met this

In 2001, reading one human genome cost about $95 million. By 2022 it cost about $525. In December 2023 the US approved the first CRISPR medicine, for sickle cell disease - which about 100,000 people have in the US alone. By September 2025, 39 patients worldwide had been infused. The reading got cheap. The fixing did not.

If this moved

If gene therapies became cheap to deliver, the longevity megatrend would still read 1 - brain-computer interfaces and longevity interventions hold it. Precision everything would stay at 2 on managerial capability, smart cities and workforce trust. Cheaper sequencing would move nothing on this map at all.

What to watch for

Patients actually infused with approved gene therapies, reported quarter by quarter - not approvals. Insurers paying for one-time cures in instalments tied to whether the treatment keeps working.

Not to be confused with

Synthetic biology. Genomics reads and edits the genetic code that exists; synthetic biology designs new biological parts and systems.

What it is

Reading, interpreting and applying biological information - sequencing, diagnostics, and the biological engineering built on them.

How it works

  1. 01DNA is cut and taggedDNA from a sample is broken into short fragments and tagged with short synthetic sequences so the machine can hold and identify each one.
  2. 02Fragments are copied in placeOn a glass flow cell, each fragment is copied into a tight cluster of identical copies, so its signal is strong enough to read.
  3. 03The machine reads one letter at a timeFluorescent bases are added one by one, and a camera records which colour lights up at each cluster.
  4. 04Software finds the differencesMillions of short reads are matched against a reference genome. Deciding which differences matter is the slow, expensive part - and it is not in the headline cost.
  5. 05Editing acts on the findingFor a CRISPR therapy, a patient's blood stem cells are collected, a guide RNA steers the Cas9 enzyme to one spot in their DNA, and the edited cells are infused back.

State of play

  • NHGRI's measured cost of sequencing a human genome fell from $95,263,072 in September 2001 to $525 in May 2022 (NHGRI, DNA Sequencing Costs: Data, updated 16 May 2023).
  • The cost first fell below $1,000 in February 2019, at $993 (NHGRI, DNA Sequencing Costs: Data, updated 16 May 2023).
  • NHGRI's cost figures leave out quality control, alignment, variant calling and annotation - the steps that turn a sequence into a finding (NHGRI, The Cost of Sequencing a Human Genome, 1 Nov 2021).
  • The FDA approved Casgevy for sickle cell disease on 8 December 2023, the first treatment it approved that uses CRISPR genome editing (FDA, 8 Dec 2023).
  • By 30 September 2025, about 165 patients worldwide had cells collected for Casgevy and 39 had been infused (CRISPR Therapeutics, 10 Nov 2025 - company-reported).
  • Lenmeldy, a gene therapy for early-onset metachromatic leukodystrophy approved on 18 March 2024, launched at a list price of $4.25 million for a one-time treatment (Orchard Therapeutics, 20 Mar 2024).

Why it matters

It converted biology from an observational science into an engineering one. Sequencing cost fell faster than semiconductor cost over the same period, which is the sharpest exponential in this book.

  • It is the book's cleanest Ramp Model case: the steepest cost curve on the map, feeding megatrends that sit at 1 and 2.
  • Longevity reads 1, held by brain-computer interfaces and longevity interventions; precision everything reads 2 on managerial capability, smart cities and workforce trust. Cheaper sequencing moves none of them.
  • A cure priced at $4.25 million is a budget problem before it is a medical one. A $525 test never was.

What holds it back

Paying for one-time cures

Gene therapies cost millions up front while the benefit arrives over decades. Health budgets are not built for that shape.

Delivery capacity

Each patient's cells are collected, edited and returned at a specialist centre. By September 2025, Casgevy had collected cells from about 165 patients and infused 39.

Interpretation and evidence

A variant found is not a variant understood. Turning a sequence into a clinical decision needs population-scale reference data and trials, and both run on slow clocks.

Terms

Next-generation sequencing (NGS)
Technology that reads millions of DNA fragments at once.
CRISPR-Cas9
A gene-editing tool: a guide RNA leads the Cas9 enzyme to a chosen spot in DNA, where it cuts.
Autologous cell therapy
A treatment in which a patient's own cells are taken out, modified and put back.
Variant calling
Identifying where a sequenced genome differs from the reference genome.
Gene therapy
A treatment that adds, removes or changes genetic material in a patient's cells.

Steepens

The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull.

If this moved one step

Computed from the map as it stands: this score raised from 3 to 4, every other score unchanged. It is arithmetic, not a forecast.

Raised one step on its own, it lifts no megatrend's weakest link; each gradient it feeds still rises a little.

The gradient also rises in

What if it moved?

What would change the gradient

Conditional, not predictive. No dates, no probabilities.

  1. 01Interpretation at population scale, which requires diverse reference data
  2. 02Clinical evidence generation, which runs on trial timescales
  3. 03Reimbursement, which decides what reaches patients

Common misconception

That falling sequencing cost translates into clinical benefit at the same rate. Interpretation, evidence generation and clinical integration are each far slower, and each is the binding constraint somewhere.

Talin, B. (2026). BioTech & Genomics. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/biotech-and-genomics/